Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 107-108, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-1009673
ABSTRACT
PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 months longer for those treated with enzalutamide (36.6 months) compared to those treated with placebo (14.7 months). Enzalutamide also showed prolonged time to PSA progression, PSA response, and time to initiating additional antineoplastic therapy although overall survival is not yet reached. Enzalutamide is the second antiandrogen (next to apalutamide) that has gained the United States Food and Drug Administration (US FDA) label indication for use in the setting of nonmetastatic castration-resistant prostate cancer.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Feniltioidantoína
/
Benzamidas
/
Neoplasias de Próstata Resistentes à Castração
/
Antagonistas de Androgênios
/
Antineoplásicos
/
Nitrilas
Limite:
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Asian Journal of Andrology
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS